Christopher Albanese

Dr. Christopher Albanese


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Cell Cycle
Verified
Journal Article
Open access
PDF file
OROlga Catalina Rodriguez
Olga Catalina Rodriguez
SCSujatra Choudhury
Sujatra Choudhury
VKVamsi K. Kolukula
Vamsi K. Kolukula
EVEveline E. Vietsch
Eveline E. Vietsch
JCJason Catania
Jason Catania
Maria Laura AvantaggiatiMaria Laura Avantaggiati
Maria Laura Avantaggiati
The majority of human tumors express mutant forms of p53 at high levels, promoting gain of oncogenic functions and correlating with disease progression, resistance to therapy and unfavorable prognosis. p53 mutant accumulation in tumors is attributed to the ability to evade degradation by the proteasome, the only currently recognized machinery for p53 disruption. We report here that glucose restriction (GR) induces p53 mutant deacetylation, routing it for degradation via autophagy. Depletion of p53 leads, in turn, to robust autophagic activation and to cell death, while expression of degradation-defective mutant p53 blocks autophagy and enables survival to GR. Furthermore, we found that a carbohydrate-free dietetic regimen that lowers the fasting glucose levels blunts p53 mutant expression and oncogenic activity relative to a normal diet in several animal model systems. These findings indicate that the stability of mutant forms of p53 is influenced by the levels of glucose and by dietetic habits. They also unravel the existence of an inhibitory loop between autophagy and mutant p53 that can be exploited therapeutically.

1 April 2013 in Cell Cycle
Verified
Journal Article
Closed access
PDF file
SCSujata Choundhury
Sujata Choundhury
VKVamsi K. Kolukula
Vamsi K. Kolukula
APAnju Preet
Anju Preet
Christopher AlbaneseChristopher Albanese
Christopher Albanese
Maria Laura AvantaggiatiMaria Laura Avantaggiati
Maria Laura Avantaggiati
One fundamental feature of mutant forms of p53 consists in their accumulation at high levels in tumors. At least in the case of neomorphic p53 mutations, which acquire oncogenic activity, stabilization is a driving force for tumor progression. It is well documented that p53 mutants are resistant to proteasome-dependent degradation compared with wild-type p53, but the exact identity of the pathways that affect mutant p53 stability is still debated. We have recently shown that macroautophagy (autophagy) provides a route for p53 mutant degradation during restriction of glucose. Here we further show that in basal conditions of growth, inhibition of autophagy with chemical inhibitors or by downregulation of the essential autophagic genes ATG1/Ulk1, Beclin-1 or ATG5, results in p53 mutant stabilization. Conversely, overexpression of Beclin-1 or ATG1/Ulk1 leads to p53 mutant depletion. Furthermore, we found that in many cell lines, prolonged inhibition of the proteasome does not stabilize mutant p53 but leads to its autophagic-mediated degradation. Therefore, we conclude that autophagy is a key mechanism for regulating the stability of several p53 mutants. We discuss plausible mechanisms involved in this newly identified degradation pathway as well as the possible role played by autophagy during tumor evolution driven by mutant p53.

1 September 2019 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
EPErika Parasido
Erika Parasido
GAGeorge S. Avetian
George S. Avetian
ANAisha Naeem
Aisha Naeem
GGGarrett Graham
Garrett Graham
MPMichael Pishvaian
Michael Pishvaian
Christopher AlbaneseChristopher Albanese
Christopher Albanese
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and, very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted to systemic chemotherapy, a therapeutic intervention to which most eventually develop resistance. Recently, nab-paclitaxel (n-PTX) has been added to the arsenal of first-line therapies, and the combination of gemcitabine and n-PTX has modestly prolonged median overall survival. However, patients almost invariably succumb to the disease, and little is known about the mechanisms underlying n-PTX resistance. Using the conditionally reprogrammed (CR) cell approach, we established and verified continuously growing cell cultures from treatment-naïve patients with PDAC. To study the mechanisms of primary drug resistance, nab-paclitaxel–resistant (n-PTX-R) cells were generated from primary cultures and drug resistance was verified in vivo, both in zebrafish and in athymic nude mouse xenograft models. Molecular analyses identified the sustained induction of c-MYC in the n-PTX-R cells. Depletion of c-MYC restored n-PTX sensitivity, as did treatment with either the MEK inhibitor, trametinib, or a small-molecule activator of protein phosphatase 2a. Implications: The strategies we have devised, including the patient-derived primary cells and the unique, drug-resistant isogenic cells, are rapid and easily applied in vitro and in vivo platforms to better understand the mechanisms of drug resistance and for defining effective therapeutic options on a patient by patient basis.

17 September 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
Xiaoxin WangXiaoxin Wang
Xiaoxin Wang
Komuraiah MyakalaKomuraiah Myakala
Komuraiah Myakala
ALAndrew E. Libby
Andrew E. Libby
EKEwa Krawczyk
Ewa Krawczyk
JPJulia Panov
Julia Panov
MLMoshe Levi
Moshe Levi

19 January 2006 in The Prostate
Verified
Journal Article
Closed access
PDF file
SFStanley T. Fricke
Stanley T. Fricke
OROlga Rodriguez
Olga Rodriguez
JVJohn VanMeter
John VanMeter
LDLuis E. Dettin
Luis E. Dettin
MCMathew Casimiro
Mathew Casimiro
Christopher AlbaneseChristopher Albanese
Christopher Albanese

15 October 2003
Verified
Journal Article
Closed access
DCDongpo Cai
Dongpo Cai
AIAnita Iyer
Anita Iyer
Kyriacos FelekkisKyriacos Felekkis
Kyriacos Felekkis
RNRichard I Near
Richard I Near
ZLZhijun Luo
Zhijun Luo
ALAdam Lerner
Adam Lerner